Bispecific antibody-mediated cytotoxicity by CD4+ and CD8(+)-activated T cells generated from leukemia patients after allogeneic bone marrow transplantation.

The F(ab') 2 bispecific antibody (BSAb) was prepared from anti-CD3 moAb and anti-CD10 moAb. The BSAb could react with both CD3 + T cells and CD10 + leukemia cells and triggered T cell-mediated cytotoxicity. To apply the BSAb to prevention of leukemic relapse after BMT, we investigated the generation of both CD4 + and CD8 + anti-tumor effector T cells from patient's PBMC 14 days after BMT. Neither CD4 + T cells nor CD8 + T cells, which were activated with immobilized anti-CD3 moAb plus IL-2, could lyse CD10 + leukemia cells by themselves, but they showed augmented cytotoxicity against CD10 + leukemia cells by targeting with anti-CD3×anti-CD10 BSAb. Moreover, the activated CD4 + T cells were demonstrated to produce IL-2 and IFN-γ when they were cultured with CD10 + leukemia cells in the presence of the BSAb. The BSAb-mediated cytotoxicity of activated T cells was demonstrated not only against the recipient leukemia cells but also against third party leukemia cells. These results suggested that anti-CD3×anti-CD10 BSAb might be a good tool to prevent relapse after BMT in combination with activated CD4 + T cells and CD8 + T cells